11-hydroxy-5,5-dioxo-6,11-dihydrodibenzothiepin | 5251-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: 11-hydroxy-5,5-dioxo-6,11-dihydrodibenzothiepin
• 英文别名: 6,11-Dihydrodibenzothiepin-11-ol 5,5-dioxide；11-Hydroxy-6,11-dihydro-dibenzothiepin-5,5-dioxid；6,11-Dihydrodibenzo[b,e]thiepin-11-ol 5,5-dioxide；5,5-dioxo-6,11-dihydrobenzo[c][1]benzothiepin-11-ol
• CAS: 5251-28-5
• 化学式: C₁₄H₁₂O₃S
• 分子量: 260.313
• InChiKey: WFAXZDYSPXYOOD-UHFFFAOYSA-N

物化性质

• 熔点：
  157 °C
• 沸点：
  501.1±50.0 °C(Predicted)
• 密度：
  1.389±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  11-hydroxy-5,5-dioxo-6,11-dihydrodibenzothiepin 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 1.17h， 生成 1-(10,10-Dioxo-10,11-dihydro-5H-10λ6-thia-dibenzo[a,d]cyclohepten-5-yl)-4-((E)-3-phenyl-allyl)-piperazine; compound with oxalic acid
  参考文献：
  名称：

  Synthesis and Biological Activity of 11-(4-(Cinnamyl)-1-piperazinyl)-6,11-dihydrodibenz(b,e)oxepin Derivatives, Potential Agents for the Treatment of Cerebrovascular Disorders.

  摘要：

  合成了一系列11-[4-（肉桂基）-1-哌嗪基]-6，11-二氢二苯并[b，e]氧芴及其相关化合物，并评价了它们对完全缺血、常压缺氧、脂质过氧化和惊厥的保护活性。通过对这一系列化合物的构效关系研究，发现了（E）-1-（3-氟-6，11-二氢二苯并[b，e]氧芑-11-基）-4-（3-苯基-2-丙烯基）哌嗪二马来酸盐（50），AJ-3941，它具有最适合的联合药理活性。

  DOI：

  10.1248/cpb.39.2564
• 作为产物：
  描述：

  6,11-dihydrodibenzo[b,e]thiepin-11-ol 在 过氧乙酸 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 溶剂黄146 为溶剂， 生成 11-hydroxy-5,5-dioxo-6,11-dihydrodibenzothiepin
  参考文献：
  名称：

  New triazine derivatives as potent modulators of multidrug resistance

  摘要：

  A series of 70 triazine derivatives have been synthesized and tested for their capacity to modulate multidrug resistance (MDR) in DC-3F/AD and KB-A1 tumor cells in vitro, in comparison with verapamil (VRP), a calcium channel antagonist currently used in therapy as an antihypertensive drug, which also shows MDR modulating activity. Among the 12 selected compounds, 16 (S9788) showed high MDR reversing properties in vitro (300- and 6-fold VRP at 5-mu-M in DC-3F/AD and KB-A1 cells, respectively) and induced a strong accumulation of adriamycin. The relationship between the increase of ADR accumulation and the fold reversal induced by these compounds and their lack of effects on the sensitive DC-3F cells suggest that they act mainly by inhibiting the P-glycoprotein (Pgp) catalyzed efflux of cytotoxic agents, as already described for a majority of MDR modulators. In vivo, in association with the antitumor drug vincristine (0.25 mg/kg), 16 (100 mg/kg) increased the TIC by 39% in mice bearing the resistant tumor cell line P388/VCR. According to these interesting properties, 16 was selected for a clinical development because it was more bioavailable than 34, even though it was less active.

  DOI：

  10.1021/jm00091a017

文献信息

• Substituted polycyclic carbamoyl pyridone derivative prodrug
  申请人：Shionogi & Co., Ltd.

  公开号：US10202379B2

  公开（公告）日：2019-02-12

  The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.

  本发明提供了一种具有抗病毒作用，特别是对流感病毒具有生长抑制活性的化合物，该化合物的一个优选实例是具有帽依赖性内切酶抑制活性的取代 3-羟基-4-吡啶酮衍生物原药。
• SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：EP2444400B1

  公开（公告）日：2018-03-28
• SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG
  申请人：Shionogi & Co., Ltd.

  公开号：EP2620436B1

  公开（公告）日：2018-05-09
• SUBSTITUTED POLYCYCLIC CARBAMOLYPYRIDONE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：US20160368921A1

  公开（公告）日：2016-12-22

  This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.
• PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：US20200339565A1

  公开（公告）日：2020-10-29

  The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.